For operators with more than one home
The 30-Day Proof.
Two of your homes. Thirty days. Judge it on day 30.
Title22 runs beside what you use today — nothing imported, nothing connected. On day 1 and day 30, Tello's briefing puts each home on one screen. Compare the two and decide.
Read it instead
Which of your homes do you look at first? Title22 runs beside what you already use, and it holds no resident health information. In the Tello tab, the portfolio briefing puts every home on one screen: one row per home, lowest first — checklist, overdue items, expired certifications, open clearances. Every number is counted by the app, not guessed by the AI. In the sandbox, the second row is an illustration: the same home with every open item closed. Then a short summary, for someone who has a minute. Two of your homes, thirty days: press the briefing on day 1 and again on day 30, and compare. No card, nothing to cancel.
How it runs
Three steps. The first one never touches your data at all.
-
The executive presentation — on sample data
We walk your leadership through Title22's public sandbox: a sample home as it is recorded, with overdue items and expired staff certifications, shown beside the same home with every open item closed. That second view is labelled as an illustration. Nobody logs into anything of yours.
-
One or two homes, 30 days
Your team signs up at title22.app and adds the one or two facilities you choose — every Title22 trial is 30 days, with no card and nothing to cancel, so there is nothing to arrange. Administrators record staff certifications and clearances, work the DSS readiness checklist, and log incidents without naming anyone — alongside what they do today, not instead of it.
-
Day 1 and day 30 briefings
On the first day and the last, Tello's portfolio briefing puts every home on one screen and summarises it for someone who has a minute. The two briefings, side by side, are the result — in your own records.
Tello, for the executive
Caregivers ask Tello what to do today. A regional director asks something else: which home do I look at first, and why? The portfolio briefing answers that — one row per home, lowest first, and a short summary written only from those numbers.
| Home | Checklist | Overdue | Staff certs expired | Clearances open | Status |
|---|---|---|---|---|---|
| Home A | 40% | 2 | 1 | 1 | Needs attention |
| Home B | 100% | 0 | 0 | 0 | On track |
An example of the layout, not a customer's figures. "Checklist" is the share of each home's Title22 checklist marked complete; each home's own dashboard score also counts staff records and filed documents.
Nothing identifying leaves the building
The briefing reads checklist status, staff certification dates and incident dates. Tello is sent home names and numbers — no resident, and no staff member by name.
The table does not depend on the AI
Every figure is counted by the app before Tello writes a word, and she is told to add none of her own. If she is unavailable, the summary is computed from the table and says so.
Unread is never "clear"
If a home's records cannot be read, the briefing says so and leaves it out of the totals. A home nobody checked is never shown as on track.
No resident health information, during the 30 days or after. Title22 holds no resident records, no medications, no MAR, no LIC 601 or LIC 602A. That is a design decision, not a trial restriction — it is what lets Title22 run without a business associate agreement. Staff certifications and clearances are employment records. Incidents are written without naming anyone.
What it costs, and what it does not promise
It is the standard 30-day free trial, with someone from Title22 alongside — no credit card, and nothing to cancel. If you continue, the plans are the ones on the pricing page: Multi-Home at $79 a month for up to five homes, or Agency for more, through sales. An account that ends without a plan becomes read-only; nothing recorded is deleted.
Title22 helps a facility see and close its open items. It does not guarantee compliance or the outcome of an inspection, and Tello never comments on clinical or dosage matters, on any plan. Anything regulatory goes to your licensing program analyst.